Trade Sumitomo Dainippon Pharma Co., Ltd. - 4506 CFD

Sumitomo Dainippon Pharma Co., Ltd. Company profile

About Sumitomo Dainippon Pharma Co Ltd

Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Company operates in four segments. The Japan segment manufactures and sells medical drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated subsidiary. The Other Overseas division is involved in the development of its products in Europe. The Company is also engaged in the manufacture, purchase, sale and supply of food materials and additives, chemical products, veterinary drugs, diagnostic products and inspection services of clinical pathology for animal, the manufacture of extracts, as well as the storage, delivery and clinical inspection of drugs.

Financial summary

BRIEF: For the nine months ended 31 December 2021, Sumitomo Dainippon Pharma Co Ltd revenues increased 9% to Y432.07B. Net income decreased 34% to Y46.36B. Revenues reflect Northern America segment increase of 15% to Y250.7B, China segment increase of 42% to Y27.03B. Net income was offset by Eliminations and Corporate segment loss increase of 19% to Y67.35B, Other segment income decrease of 3% to Y2.78B. Dividend per share remained flat at Y14.00.

Equity composition

10/2005, Company name changed from Dainippon C Co., Ltd. and 229,716,000 shares increased dut to the merger FY'94-'02 WAS, & FY'05-'06 1&3Q, FY'08 1Q&3Q O/S & WAS were estimated.